



## ***Shilpa Medicare Limited***

### **Corporate & Admin Office:**

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbshilpa.com, Web: www.vbshilpa.com  
CIN: L85110KA1987PLC008739

**Date: 04 September 2024**

To,  
Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**Mumbai-400 051**

**Stock Code: BSE – 530549 / NSE – SHILPAMED**

Dear Sir/Madam,

**Sub: Shilpa Medicare announces submission of NDA to U.S. FDA by Unicycive - Its First Regulatory submissions from CDMO partnered projects**

**Ref: - Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Announces Submission of NDA to U.S. FDA for Oxylanthanum Carbonate for Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis.

The NDA submission package is based on data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, and the specifications and practices related to chemistry, manufacturing and controls (CMC).

Unicycive has partnered with SML to provide end-to-end CDMO services right from development of APIs & formulation to supply of finished dosage form. Unicycive has entered into long term manufacturing and supply agreement with SML for all its commercial requirements in the market starting from Q1 – FY 2025-26.



## ***Shilpa Medicare Limited***

### **Corporate & Admin Office:**

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbshilpa.com, Web: www.vbshilpa.com  
CIN: L85110KA1987PLC008739

Commenting on the event, Mr. Vishnukant Bhutada – Managing Director, Shilpa Medicare Limited mentioned, “Submission of this NDA demonstrates delivery of high quality developmental services by Shilpa to its CDMO customers and strengthens its credentials as a one-stop reliable partner for all the CDMO requirements of global pharma companies. We are very pleased to have partnered with a like-minded team of Unicycive to deliver path breaking treatments for patients suffering from chronic diseases.”

### About Shilpa:

Shilpa is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its strong R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.

Thanking you,  
For **Shilpa Medicare Limited**

**Ritu Tiwary**  
**Company Secretary & Compliance Officer**